The earnings call reflects a positive overall sentiment with significant progress in the pipeline, particularly with the upcoming brepocitinib data, a strong financial position, and strategic share repurchase programs. However, challenges remain with ongoing LNP litigation and complexities in clinical trial management.

Company Guidance

In the Roivant First Quarter 2025 earnings call, CEO Matt Gline provided guidance on several key developments and metrics. The company highlighted three main themes for 2025, focusing on the progress with IMVT-1402 and Immunovant, the upcoming data from the pivotal trial of brepocitinib, and ongoing litigation with Moderna. Roivant has completed the last patient visit for the brepocitinib trial, with data expected in the second half of the year, potentially leading to a commercial launch. The company has also been active in share repurchase, completing a $1.5 billion program and authorizing an additional $500 million. Financially, Roivant reported an adjusted net loss of $170 million, with cash utilization of $200 million outside of the share repurchase program, and maintains a strong balance sheet with $4.5 billion in cash and no debt as of June 30, 2025. Roivant is preparing for a potential commercial launch in dermatomyositis (DM) and continues to advance its pipeline, with multiple registrational trials ongoing.

Upcoming Brepocitinib Data

Brepocitinib, a drug with a well-established safety profile in over 1,500 patients, is approaching a pivotal trial data release that could redefine the standard of care for dermatomyositis (DM).

Share Repurchase Program

Completed a $1.5 billion share repurchase program, reducing share count by over 15%. An additional $500 million repurchase program has been authorized.

Strong Financial Position

Roivant holds $4.5 billion in cash with no debt, providing a strong financial position for future growth and development.

Pipeline Progress

Significant progress across the pipeline, including multiple registrational trials for IMVT-1402 and rapid advancement of brepocitinib in various indications.

Roivant Sciences (ROIV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ROIV Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q2)	-0.31 / -	-0.31	―	―	―
Aug 11, 2025	2025 (Q1)	-0.25 / -0.25	0.12	-310.00% (-0.37)
May 29, 2025	2024 (Q4)	-0.26 / -0.29	-0.19	-52.63% (-0.10)
Feb 10, 2025	2024 (Q3)	-0.25 / 0.23	6.03	-96.19% (-5.80)
Nov 12, 2024	2024 (Q2)	-0.25 / -0.31	-0.263	-17.87% (-0.05)
Aug 08, 2024	2024 (Q1)	-0.24 / 0.12	-0.227	152.86% (+0.35)
May 30, 2024	2023 (Q4)	-0.26 / -0.19	-0.219	13.24% (+0.03)
Feb 13, 2024	2023 (Q3)	-0.31 / 6.03	-0.414	1556.52% (+6.44)
Nov 13, 2023	2023 (Q2)	-0.29 / -0.26	-0.293	10.24% (+0.03)
Aug 14, 2023	2023 (Q1)	-0.28 / -0.23	-0.48	52.71% (+0.25)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ROIV Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$11.49	$11.17	-2.79%
May 29, 2025	$10.62	$11.30	+6.40%
Feb 10, 2025	$10.89	$10.79	-0.92%
Nov 12, 2024	$11.81	$11.64	-1.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Roivant Sciences (ROIV) report earnings?

Roivant Sciences (ROIV) is schdueled to report earning on Nov 17, 2025, Before Open (Confirmed).

What is Roivant Sciences (ROIV) earnings time?

Roivant Sciences (ROIV) earnings time is at Nov 17, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ROIV EPS forecast?

ROIV EPS forecast for the fiscal quarter 2025 (Q2) is -0.31.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing